4-氨基-1-(5-乙氧基羰基吡啶-2-基)哌啶 | 252577-91-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氨基-1-(5-乙氧基羰基吡啶-2-基)哌啶
• 英文名称: 4-amino-1-(5-ethoxycarbonylpyrid-2-yl)piperidine
• 英文别名: 4-amino-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid ethyl ester；6-(4-aminopiperidin-1-yl)nicotinic acid ethyl ester；3-Pyridinecarboxylic acid, 6-(4-amino-1-piperidinyl)-, ethyl ester；ethyl 6-(4-aminopiperidin-1-yl)pyridine-3-carboxylate
• CAS: 252577-91-6
• 化学式: C₁₃H₁₉N₃O₂
• mdl: MFCD12428291
• 分子量: 249.313
• InChiKey: ZLZGWYCDEZAFBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  68.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-氨基-1-(5-乙氧基羰基吡啶-2-基)哌啶 、 (S)-3-(2-amino-3-nitrophenoxy)-1,2-epoxypropane 以 乙醇 为溶剂， 生成 3-[1-(5-ethoxycarbonylpyrid-2-yl)-4-piperidinyl-amino]-1-(2-amino-3-nitrophenoxy)-2-propanol
  参考文献：
  名称：

  Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same

  摘要：

  公式（I）的化合物：其中X为N或CH；A代表公式（a）或（b）的基团；R1代表氢或—NH2，—NR3R4，—NR3CO（C1-C4）Alk或—NR3SO2（C1-C4）Alk基团；R2代表氢，卤素或（C1-C4）Alk，（C1-C4）alkoxy，—COOH，—COO（C1-C4）Alk，—CN，—CONR3R4，—NO2，—SO2NR3R4或—NHSO2（C1-C4）Alk；m和n分别表示0、1或2；R3和R4各自表示氢或（C1-C4）Alk基团；Y1和Y2各自表示NH或O；以及它们的盐或溶剂化合物，其制备方法和包含它们的药物组合物。

  公开号：

  US06858629B1
• 作为产物：
  描述：

  哌啶-4-甲酰胺 在 N,N-二异丙基乙胺 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 水 、 二甲基亚砜 、 乙腈 为溶剂， 反应 32.0h， 生成 4-氨基-1-(5-乙氧基羰基吡啶-2-基)哌啶
  参考文献：
  名称：

  WO2007/121918

  摘要：

  公开号：

文献信息

• Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
  申请人：Sanofi-Synthelabo

  公开号：US06649627B1

  公开（公告）日：2003-11-18

  The invention concerns compounds of formula (Ia) wherein R1a represents hydrogen, an —S(O)z —(C1-C4)Alk group, a —CO(C1-C4)Alk group, an —NHSO2—(C1-C4)Alk group, an NCHl (C1-C4) Alk group, a 2-furyl group or a halogen; R2 represents hydrogen or a (C1-C4)Alk group, a (C1-C4) alkoxyl group, a halogen, —COOH, —COO(C1-C4)Alk, —CN, —CONR3R4, —NO2, —SO2NH2, —NHSO2(C1-C4)Alk; m and n are independently 0, 1 or 2; R3 and R4 independently represent hydrogen or a (C1-C4)Alk group; Z is 1 or 2 and their salts or solvates, the pharmaceutical compositions that contain them, the process for their preparation, and intermediate synthesis products.

  该发明涉及式（Ia）的化合物，其中R1a代表氢，一个-S(O)z-(C1-C4)Alk基团，一个-CO(C1-C4)Alk基团，一个-NHSO2-(C1-C4)Alk基团，一个NCHl（C1-C4）Alk基团，一个2-呋喃基团或一个卤素；R2代表氢或一个（C1-C4）Alk基团，一个（C1-C4）烷氧基基团，一个卤素，-COOH，-COO（C1-C4）Alk，-CN，-CONR3R4，-NO2，-SO2NH2，-NHSO2（C1-C4）Alk；m和n独立地为0、1或2；R3和R4独立地代表氢或一个（C1-C4）Alk基团；Z为1或2及其盐或溶剂化合物，包含它们的药物组合物，其制备方法以及中间合成产物。
• Phenoxypropanolamines, preparation and therapeutic use thereof
  申请人：——

  公开号：US20030105135A1

  公开（公告）日：2003-06-05

  The invention concerns phenoxypropanolamines of formula (I) wherein: R 1 represents a hydrogen, a —S(O) z —(C 1 -C 4 )Alk-R′ group, R′ being H, phenyl or (C 1 -C 4 ) alkoxy), —NHSO 2 —(C 1 -C 4 ) Alk, NHCO(C 1 -C 4 ) Alk; m and n are each independently 0, 1 or 2; R 2 and R 3 represent independently a hydrogen, a (C 5 -C 6 ) alkyl, (C 3 -C 6 ) cycloalkyl, (C 1 -C 4 ) alkoxy, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 ) alkoxy-(C 1 -C 4 )alkyl, mono-or di-(C 1 -C 4 )Alk-amino(C 1 -C 4 )alkyl, pyrrolidino-(C 1 -C 4 )alkyl, phenylamino, (C 2 -C 4 )alkenyl group, or an aromatic or heteroaromatic group substituted or not with a group R 4 ; R 2 and R 3 can also together constitute a saturated or unsaturated cycle of 3 to 6 atoms capable of bearing a (C 1 -C 4 ) alkyl, amino(C 1 -C 4 )alkyl, carbamoyl or benzyl substituent; R 4 represents a hydrogen or a halogen, a —CO(C 1 -C 4 )Alk group or a —NHSO 2 —(C 1 -C 4 )Alk group; a (C 1 -C 4 )Alk group, a (C 1 -C 4 )alkoxy group, a halogen, —COOH, —COO(C 1 -C 4 )Alk, —CN, —CONR 3 R 4 , —NO 2 , —SO 2 NH 2 , —NHSO 2 (C 1 -C 4 )Alk; z is 1 or 2; and their salts and solvates. Said compounds have an agonist activity with respect to &bgr;-3 adrenergic receptors.

  该发明涉及化合物(I)，其中：R1代表氢，—S(O)z—(C1-C4)Alk-R′基团，其中R′为H、苯基或(C1-C4)烷氧基，—NHSO2—(C1-C4)Alk，NHCO(C1-C4)Alk；m和n各自独立地为0、1或2；R2和R3分别独立地代表氢、(C5-C6)烷基、(C3-C6)环烷基、(C1-C4)烷氧基、羟基(C1-C4)烷基、(C1-C4)烷氧基-(C1-C4)烷基、单或双-(C1-C4)Alk-氨基(C1-C4)烷基、吡咯烷基-(C1-C4)烷基、苯基氨基、(C2-C4)烯基基团，或被取代或未取代的芳香或杂芳基团，该基团取代或未取代有一个R4基团；R2和R3还可以共同构成3到6个原子的饱和或不饱和环，能够承载(C1-C4)烷基、氨基(C1-C4)烷基、氨基甲酰基或苄基取代基；R4代表氢或卤素，—CO(C1-C4)Alk基团或—NHSO2—(C1-C4)Alk基团；(C1-C4)Alk基团、(C1-C4)烷氧基、卤素、—COOH、—COO(C1-C4)Alk、—CN、—CONR3R4、—NO2、—SO2NH2、—NHSO2(C1-C4)Alk；z为1或2；以及它们的盐和溶剂化合物。这些化合物对β-3肾上腺素能受体具有激动剂活性。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20080207648A1

  公开（公告）日：2008-08-28

  Compounds of formula I in free or salt form, wherein R 1 , R 2 and R 3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A 2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式I的化合物，无论是自由形式还是盐形式，其中R1、R2和R3的含义如规范中所示，对于治疗由腺苷A2A受体激活介导的炎症或阻塞性呼吸道疾病非常有用。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• Organic compounds
  申请人：Novartis AG

  公开号：US08114877B2

  公开（公告）日：2012-02-14

  Compounds of formula I in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  化学式I的化合物（以自由形式或盐形式存在），其中R1、R2和R3的含义如规范中所示，可用于治疗通过激活腺苷A2A受体介导的疾病，特别是炎症性或阻塞性呼吸道疾病。还描述了包含这些化合物的制药组合物和制备这些化合物的过程。
• Piperazine compound having a PGDS inhibitory effect
  申请人：Urade Yoshihiro

  公开号：US08765750B2

  公开（公告）日：2014-07-01

  The present invention provides a piperazine compound represented by Formula (I) or a salt thereof, wherein X represents CH or an N atom; R1 represents C1-6 alkyl; R2 represents C1-6 alkyl that may have one or more substituents, C2-6 alkenyl that may have one or more substituents, —(C═O)—N(R3)(R4), or —(C═O)—OR5, R3 and R4 are the same or different, and each represents hydrogen or C1-6 alkyl that may have one or more substituents; or R3 and R4, taken together with a nitrogen atom to which R3 and R4 are attached, may form a saturated heterocyclic group; and R5 represents hydrogen or C1-6 alkyl that may have one or more substituents or aralkyl.

  本发明提供了一种由式（I）表示的哌嗪化合物或其盐，其中X代表CH或N原子；R1代表C1-6烷基；R2代表C1-6烷基，可能具有一个或多个取代基，C2-6烯基，可能具有一个或多个取代基，-(C═O)-N(R3)(R4)，或-(C═O)-OR5，其中R3和R4相同或不同，每个都代表氢或C1-6烷基，可能具有一个或多个取代基；或R3和R4与R3和R4附着的氮原子一起形成饱和杂环基；R5代表氢或C1-6烷基，可能具有一个或多个取代基或芳基烷基。